{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T01:14:54Z","timestamp":1788052494801,"version":"build-2784847793"},"reference-count":225,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100008856","name":"Zhejiang Province Health Bureau","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008856","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004731","name":"Zhejiang Province Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.ejmech.2026.119190","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T06:11:13Z","timestamp":1785132673000},"page":"119190","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Targeted radionuclide-drug conjugates: Current status and perspectives"],"prefix":"10.1016","volume":"318","author":[{"given":"Yichao","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiyu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanni","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3869-105X","authenticated-orcid":false,"given":"Lidan","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2026.119190_bib1","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14020297","article-title":"Radionuclides in diagnostics and therapy of malignant tumors: new development","volume":"14","author":"Tolmachev","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ejmech.2026.119190_bib2","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41392-023-01366-y","article-title":"Molecular and functional imaging in cancer-targeted therapy: current applications and future directions","volume":"8","author":"Bai","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.119190_bib3","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s41392-024-01853-w","article-title":"Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade","volume":"9","author":"Zhao","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.119190_bib4","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1007\/s00259-024-06726-6","article-title":"Development and first-in-human study of PSMA-targeted PET tracers with improved pharmacokinetic properties","volume":"51","author":"Hou","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2026.119190_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-024-02041-6","article-title":"Radiopharmaceuticals and their applications in medicine","volume":"10","author":"Zhang","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.119190_bib6","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s40291-024-00702-4","article-title":"Advances in radioligand theranostics in oncology","volume":"28","author":"Lawal","year":"2024","journal-title":"Mol. Diagn. Ther."},{"key":"10.1016\/j.ejmech.2026.119190_bib7","doi-asserted-by":"crossref","DOI":"10.3390\/ph15010013","article-title":"Expanding Theranostic radiopharmaceuticals for tumor diagnosis and therapy","volume":"15","author":"Barca","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.ejmech.2026.119190_bib8","doi-asserted-by":"crossref","first-page":"103","DOI":"10.7150\/ntno.64141","article-title":"Radiotheranostics - precision medicine in nuclear medicine and molecular imaging","volume":"6","author":"Duan","year":"2022","journal-title":"Nanotheranostics"},{"key":"10.1016\/j.ejmech.2026.119190_bib9","first-page":"847","article-title":"Radionuclide drug conjugates: China's 15-Year research and development process and latest policy support","volume":"16","author":"Dan","year":"2025","journal-title":"Med. J. Peking Union Med. Coll. Hosp."},{"key":"10.1016\/j.ejmech.2026.119190_bib10","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1097\/MNM.0000000000001832","article-title":"Selection of radionuclide(s) for targeted alpha therapy based on their nuclear decay properties","volume":"45","author":"Ree","year":"2024","journal-title":"Nucl. Med. Commun."},{"key":"10.1016\/j.ejmech.2026.119190_bib11","doi-asserted-by":"crossref","first-page":"3981","DOI":"10.1007\/s00259-022-05860-3","article-title":"Repair of \u03b1-particle-induced DNA damage in peripheral blood mononuclear cells after internal ex vivo irradiation with 223Ra","volume":"49","author":"G\u00f6ring","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2026.119190_bib12","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1038\/s41467-022-29630-9","article-title":"Multimodal CEA-targeted fluorescence and radioguided cytoreductive surgery for peritoneal metastases of colorectal origin","volume":"13","author":"de Gooyer","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2026.119190_bib13","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1152\/physrev.00049.2010","article-title":"A molecular imaging primer: modalities, imaging agents, and applications","volume":"92","author":"James","year":"2012","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.ejmech.2026.119190_bib14","doi-asserted-by":"crossref","first-page":"423","DOI":"10.2967\/jnumed.125.270987","article-title":"Quantitative comparison of SPECT and PET performance for clinical theranostic applications","volume":"67","author":"Salerno","year":"2026","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2026.119190_bib15","doi-asserted-by":"crossref","first-page":"83","DOI":"10.2967\/jnumed.112.111476","article-title":"An evidence-based review of quantitative SPECT imaging and potential clinical applications","volume":"54","author":"Bailey","year":"2013","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2026.119190_bib16","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1631\/jzus.B1400131","article-title":"Therapeutic radionuclides in nuclear medicine: current and future prospects","volume":"15","author":"Yeong","year":"2014","journal-title":"J. Zhejiang Univ. - Sci. B"},{"key":"10.1016\/j.ejmech.2026.119190_bib17","series-title":"Methods to Assess the Biodistribution of Radiolabelled Somatostatin Analogues and Treatment Response of Neuroendocrine Tumours","author":"Gnanasegaran","year":"2004"},{"key":"10.1016\/j.ejmech.2026.119190_bib18","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s10555-005-6195-z","article-title":"Antibody-guided radiation therapy of cancer","volume":"24","author":"Koppe","year":"2005","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ejmech.2026.119190_bib19","first-page":"321","article-title":"Toxicity and relative biological effectiveness of alpha emitting radioimmunoconjugates","volume":"4","author":"Dahle","year":"2011","journal-title":"Curr. Rad."},{"key":"10.1016\/j.ejmech.2026.119190_bib20","first-page":"36","article-title":"Peptide imaging with somatostatin analogues: more than cancer probes","volume":"6","author":"Lucio Cascini","year":"2013","journal-title":"Curr. Rad."},{"key":"10.1016\/j.ejmech.2026.119190_bib21","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1007\/s00259-012-2156-2","article-title":"Toward tailored medicine (and beyond): the phaeochromocytoma and paraganglioma model","volume":"39","author":"Cuccurullo","year":"2012","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2026.119190_bib22","doi-asserted-by":"crossref","first-page":"3355","DOI":"10.1039\/D0CS00384K","article-title":"Radiolabelling of nanomaterials for medical imaging and therapy","volume":"50","author":"Pellico","year":"2021","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ejmech.2026.119190_bib23","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0064730","article-title":"Alpha-particle emitting 213Bi-anti-EGFR immunoconjugates eradicate tumor cells independent of oxygenation","volume":"8","author":"Wulbrand","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.119190_bib24","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3390\/ph8020321","article-title":"A critical review of alpha radionuclide therapy\u2014how to deal with recoiling daughters?","volume":"8","author":"De Kruijff","year":"2015","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2026.119190_bib25","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1088\/0031-9155\/56\/3\/012","article-title":"Renal uptake of bismuth-213 and its contribution to kidney radiation dose following administration of actinium-225-labeled antibody","volume":"56","author":"Schwartz","year":"2011","journal-title":"Phys. Med. Biol."},{"key":"10.1016\/j.ejmech.2026.119190_bib26","series-title":"Reducing Renal Uptake of Free 213Bi Associated with the Decay of 225Ac-labeled Radiopharmaceuticals","author":"Nedrow","year":"2017"},{"key":"10.1016\/j.ejmech.2026.119190_bib27","doi-asserted-by":"crossref","DOI":"10.1118\/1.4881329","article-title":"Correlation between energy deposition and molecular damage from Auger electrons: a case study of ultra\u2010low energy (5\u201318 eV) electron interactions with DNA","volume":"41","author":"Rezaee","year":"2014","journal-title":"Med. Phys."},{"key":"10.1016\/j.ejmech.2026.119190_bib28","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/B978-0-12-822960-6.00137-X","article-title":"Basics of radiobiology","volume":"1","author":"Pouget","year":"2022","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.ejmech.2026.119190_bib29","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1053\/j.semnuclmed.2024.02.003","article-title":"Radiotheranostics global market and future developments","volume":"54","author":"Al-Ibraheem","year":"2024","journal-title":"Semin. Nucl. Med."},{"key":"10.1016\/j.ejmech.2026.119190_bib30","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s41181-025-00339-6","article-title":"Mitochondria-tropic radioconjugates to enhance the therapeutic potential of terbium-161","volume":"10","author":"Santos","year":"2025","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"10.1016\/j.ejmech.2026.119190_bib31","doi-asserted-by":"crossref","first-page":"878","DOI":"10.2967\/jnumed.116.186338","article-title":"\u03b1-emitters for radiotherapy: from basic radiochemistry to clinical studies\u2014part 1","volume":"59","author":"Poty","year":"2018","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2026.119190_bib32","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.2967\/jnumed.114.153502","article-title":"Monte Carlo evaluation of Auger electron-emitting theranostic radionuclides","volume":"56","author":"Falzone","year":"2015","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2026.119190_bib33","article-title":"Trends in the research and development of peptide drug conjugates: artificial intelligence aided design","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119190_bib34","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s44303-024-00027-1","article-title":"New tactics in the design of theranostic radiotracers","volume":"2","author":"Berton","year":"2024","journal-title":"Npj Imaging"},{"key":"10.1016\/j.ejmech.2026.119190_bib35","doi-asserted-by":"crossref","first-page":"50000","DOI":"10.1021\/acsomega.4c09450","article-title":"In vitro and in vivo comparison of random versus site-specific conjugation of bifunctional chelating agents to the CD33-Binding antibody for use in Alpha- and beta-radioimmunotherapy","volume":"9","author":"Allen","year":"2024","journal-title":"ACS Omega"},{"key":"10.1016\/j.ejmech.2026.119190_bib36","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1021\/bc200288d","article-title":"Modular strategy for the construction of radiometalated antibodies for positron emission tomography based on inverse electron demand diels\u2013alder click chemistry","volume":"22","author":"Zeglis","year":"2011","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2026.119190_bib37","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/nchembio.720","article-title":"Choosing an effective protein bioconjugation strategy","volume":"7","author":"Stephanopoulos","year":"2011","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119190_bib38","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1021\/bc5004982","article-title":"Site-specific antibody-drug conjugates: the nexus of bioorthogonal chemistry, protein engineering, and drug development","volume":"26","author":"Agarwal","year":"2015","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2026.119190_bib39","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/nbt.2968","article-title":"Self-hydrolyzing maleimides improve the stability and pharmacological properties of antibody-drug conjugates","volume":"32","author":"Lyon","year":"2014","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ejmech.2026.119190_bib40","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24193567","article-title":"Recent advances in bioorthogonal click chemistry for efficient synthesis of radiotracers and radiopharmaceuticals","volume":"24","author":"Mushtaq","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119190_bib41","doi-asserted-by":"crossref","DOI":"10.1038\/s43586-021-00028-z","article-title":"Bioorthogonal chemistry","volume":"1","author":"Scinto","year":"2021","journal-title":"Nat. Rev. Methods Primers"},{"key":"10.1016\/j.ejmech.2026.119190_bib42","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/nchembio.2007.31","article-title":"Sortagging: a versatile method for protein labeling","volume":"3","author":"Popp","year":"2007","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ejmech.2026.119190_bib43","article-title":"Radiopharmaceuticals and their applications in medicine","volume":"10","author":"Zhang","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.119190_bib44","first-page":"152","article-title":"Targeted radionuclide therapy-an overview","volume":"6","author":"Dash","year":"2013","journal-title":"Curr. Rad."},{"key":"10.1016\/j.ejmech.2026.119190_bib45","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41420-023-01778-3","article-title":"Carrier systems of radiopharmaceuticals and the application in cancer therapy","volume":"10","author":"Zhang","year":"2024","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.ejmech.2026.119190_bib46","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1002\/bies.20805","article-title":"Multivalency: the hallmark of antibodies used for optimization of tumor targeting by design","volume":"30","author":"Deyev","year":"2008","journal-title":"Bioessays"},{"key":"10.1016\/j.ejmech.2026.119190_bib47","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1516419","article-title":"Antibody-drug conjugates in cancer therapy: applications and future advances","volume":"16","author":"Long","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2026.119190_bib48","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1446414","article-title":"HER2-targeted therapies for HER2-positive early-stage breast cancer: present and future","volume":"15","author":"Xu","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119190_bib49","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1038\/s12276-023-01016-x","article-title":"Peptides as multifunctional players in cancer therapy","volume":"55","author":"Vadevoo","year":"2023","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ejmech.2026.119190_bib50","doi-asserted-by":"crossref","first-page":"716","DOI":"10.2967\/jnumed.111.098988","article-title":"99mTc-3PRGD2 for integrin receptor imaging of lung cancer: a multicenter study","volume":"53","author":"Zhu","year":"2012","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2026.119190_bib51","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.3348\/kjr.2023.0411","article-title":"99mTc-3PRGD2 SPECT\/CT imaging for diagnosing lymph node metastasis of primary malignant lung tumors","volume":"24","author":"Xiao","year":"2023","journal-title":"Korean J. Radiol."},{"key":"10.1016\/j.ejmech.2026.119190_bib52","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1148\/radiol.2016150813","article-title":"Integrin imaging with 99mTc-3PRGD2 SPECT\/CT shows high specificity in the diagnosis of lymph node metastasis from non\u2013small cell lung cancer","volume":"281","author":"Jin","year":"2016","journal-title":"Radiology"},{"key":"10.1016\/j.ejmech.2026.119190_bib53","article-title":"Advances in clinical oncology research on 99mTc-3PRGD2 SPECT imaging","volume":"12","author":"Xiao","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2026.119190_bib54","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.apsb.2024.10.012","article-title":"Safety, pharmacokinetics, and dosimetry of 177Lu-AB-3PRGD2 in patients with advanced integrin \u03b1v\u03b23-positive tumors: a first-in-human study","volume":"15","author":"Sui","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2026.119190_bib55","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3109\/08820139.2010.542228","article-title":"Nanobody; an old concept and new vehicle for immunotargeting","volume":"40","author":"Rahbarizadeh","year":"2011","journal-title":"Immunol. Investig."},{"key":"10.1016\/j.ejmech.2026.119190_bib56","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3390\/antib8020028","article-title":"David vs. Goliath: the structure, function, and clinical prospects of antibody fragments","volume":"8","author":"Bates","year":"2019","journal-title":"Antibodies"},{"key":"10.1016\/j.ejmech.2026.119190_bib57","doi-asserted-by":"crossref","first-page":"2600","DOI":"10.1002\/med.22057","article-title":"Rethinking therapeutic strategies of dual\u2010target drugs: an update on pharmacological small\u2010molecule compounds in cancer","volume":"44","author":"Yang","year":"2024","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2026.119190_bib58","series-title":"A New Series of PSMA-Targeting Inhibitors for astatine-211 Targeted Radionuclide Therapy of Prostate Cancer","author":"El Fakiri","year":"2022"},{"key":"10.1016\/j.ejmech.2026.119190_bib59","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1016\/j.jconrel.2023.07.060","article-title":"New liposome-radionuclide-chelate combination for tumor targeting and rapid healthy tissue clearance","volume":"361","author":"Umeda","year":"2023","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejmech.2026.119190_bib60","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1039\/D2SC06413H","article-title":"A tumor-targetable NIR probe with photoaffinity crosslinking characteristics for enhanced imaging-guided cancer phototherapy","volume":"14","author":"Sun","year":"2023","journal-title":"Chem. Sci."},{"key":"10.1016\/j.ejmech.2026.119190_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2020.120220","article-title":"Biosynthetic molecular imaging probe for tumor-targeted dual-modal fluorescence\/magnetic resonance imaging","volume":"256","author":"Zhao","year":"2020","journal-title":"Biomaterials"},{"key":"10.1016\/j.ejmech.2026.119190_bib62","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1158\/0008-5472.CAN-20-3822","article-title":"Transient competitive inhibition bypasses the binding site barrier to improve tumor penetration of trastuzumab and enhance T-DM1 efficacy","volume":"81","author":"Bordeau","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119190_bib63","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1515\/dx-2023-0108","article-title":"Tumor heterogeneity: how could we use it to achieve better clinical outcomes?","volume":"11","author":"Yousef","year":"2024","journal-title":"Diagnosis (Berl)"},{"key":"10.1016\/j.ejmech.2026.119190_bib64","article-title":"Therapeutic strategies of dual-target small molecules to overcome drug resistance in cancer therapy","volume":"1878","author":"Ye","year":"2023","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.ejmech.2026.119190_bib65","doi-asserted-by":"crossref","first-page":"7114","DOI":"10.1038\/s41598-021-86551-1","article-title":"A prostate-specific membrane antigen (PSMA)-targeted prodrug with a favorable in vivo toxicity profile","volume":"11","author":"Boinapally","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.119190_bib66","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.eururo.2023.11.018","article-title":"Prostate-specific membrane antigen-targeted therapies for prostate cancer: towards improving therapeutic outcomes","volume":"85","author":"Corpetti","year":"2024","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejmech.2026.119190_bib67","doi-asserted-by":"crossref","first-page":"213","DOI":"10.21315\/mjms2024.31.4.17","article-title":"Unveiling the potential of prostate-specific membrane antigen for precision diagnosis and therapy of prostate cancer: a radiopharmaceutical perspective","volume":"31","author":"Hassan","year":"2024","journal-title":"Malays. J. Med. Sci."},{"key":"10.1016\/j.ejmech.2026.119190_bib68","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.2967\/jnumed.120.243295","article-title":"Radionuclide therapy in prostate cancer: from standalone to combination PSMA theranostics","volume":"62","author":"Sandhu","year":"2021","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2026.119190_bib69","doi-asserted-by":"crossref","first-page":"4276","DOI":"10.3390\/cancers14174276","article-title":"A treatment paradigm shift: targeted radionuclide therapies for metastatic castrate resistant prostate cancer","volume":"14","author":"Parent","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2026.119190_bib70","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11864-025-01296-7","article-title":"Advances in PSMA-targeted radionuclide therapeutics","volume":"26","author":"Ruder","year":"2025","journal-title":"Curr. Treat. Options Oncol."},{"key":"10.1016\/j.ejmech.2026.119190_bib71","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","article-title":"PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [(177)Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial","volume":"23","author":"Buteau","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2026.119190_bib72","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1021\/acs.molpharmaceut.3c00987","article-title":"177)Lu-Labeled bivalent ligands of prostate-specific membrane antigen for endoradiotherapy of prostate cancer","volume":"21","author":"Dai","year":"2024","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2026.119190_bib73","article-title":"Current status of PSMA-targeted imaging and therapy","volume":"13","author":"Wang","year":"2023","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2026.119190_bib74","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14102166","article-title":"Advances in (177)Lu-PSMA and (225)Ac-PSMA radionuclide therapy for metastatic castration-resistant prostate cancer","volume":"14","author":"Ling","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2026.119190_bib75","doi-asserted-by":"crossref","first-page":"2794","DOI":"10.1007\/s00259-024-06721-x","article-title":"Comparison of novel PSMA-targeting [(177)Lu]Lu-P17-087 with its albumin binding derivative [(177)Lu]Lu-P17-088 in metastatic castration-resistant prostate cancer patients: a first-in-human study","volume":"51","author":"Li","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2026.119190_bib76","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1007\/s00259-024-06959-5","article-title":"Experience of rescue therapy with [(177)Lu]Lu-rhPSMA-10.1 in patients with primary or acquired resistance to [(177)Lu]Lu-PSMA-I&T","volume":"52","author":"G\u00e4ble","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2026.119190_bib77","first-page":"1033","article-title":"Overview of selected completed prospective studies on PSMA-targeted radioligand therapy with [177Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer","volume":"197","author":"Karimzadeh","year":"2025","journal-title":"R\u00f6fo"},{"key":"10.1016\/j.ejmech.2026.119190_bib78","first-page":"354","article-title":"Theranostics of metastatic prostate cancer applying 64Cu\/18F\/68Ga PSMA PET-CT and 177Lu radiopharmaceuticals","volume":"14","author":"Mirzaei","year":"2021","journal-title":"Curr. Rad."},{"key":"10.1016\/j.ejmech.2026.119190_bib79","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2967\/jnmt.122.264928","article-title":"Clinical trials of prostate-specific membrane antigen radiopharmaceutical therapy","volume":"51","author":"Jadvar","year":"2023","journal-title":"J. Nucl. Med. Technol."},{"key":"10.1016\/j.ejmech.2026.119190_bib80","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1230251","article-title":"Current status of PSMA-targeted imaging and therapy","volume":"13","author":"Wang","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2026.119190_bib81","doi-asserted-by":"crossref","first-page":"16","DOI":"10.2967\/jnmt.122.264928","article-title":"Clinical trials of prostate-specific membrane antigen radiopharmaceutical therapy","volume":"51","author":"Jadvar","year":"2023","journal-title":"J. Nucl. Med. Technol."},{"key":"10.1016\/j.ejmech.2026.119190_bib82","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.eururo.2023.11.018","article-title":"Prostate-Specific membrane antigen\u2013targeted therapies for prostate cancer: towards improving therapeutic outcomes","volume":"85","author":"Corpetti","year":"2024","journal-title":"Eur. Urol."},{"key":"10.1016\/j.ejmech.2026.119190_bib83","doi-asserted-by":"crossref","first-page":"349","DOI":"10.2967\/jnumed.122.265194","article-title":"Clinical implementation of (177)Lu-PSMA-617 in the United States: lessons learned and ongoing challenges","volume":"64","author":"Ravi","year":"2023","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2026.119190_bib84","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","article-title":"PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial","volume":"23","author":"Buteau","year":"2022","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejmech.2026.119190_bib85","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1080\/14737140.2023.2247562","article-title":"PSMA-targeted radioligand therapy in prostate cancer: current status and future prospects","volume":"23","author":"Parghane","year":"2023","journal-title":"Expert Rev. Anticancer Ther."},{"key":"10.1016\/j.ejmech.2026.119190_bib86","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1007\/s00259-024-06705-x","article-title":"Targeted interleukin-2 enhances the in vivo anti-cancer activity of Pluvicto","volume":"51","author":"Georgiev","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2026.119190_bib87","doi-asserted-by":"crossref","first-page":"692","DOI":"10.3390\/ph16050692","article-title":"Characterization of non-specific uptake and retention mechanisms of [177Lu]Lu-PSMA-617 in the salivary glands","volume":"16","author":"Heynickx","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2026.119190_bib88","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.3390\/cancers14112691","article-title":"Addition of standard enzalutamide medication shows synergistic effects on response to [177Lu]Lu-PSMA-617 radioligand therapy in mCRPC patients with imminent treatment failure\u2014Preliminary evidence of pilot experience","volume":"14","author":"Rosar","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2026.119190_bib89","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00259-019-04612-0","article-title":"(225)Ac-PSMA-617\/(177)Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience","volume":"47","author":"Khreish","year":"2020","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2026.119190_bib90","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s00259-019-04612-0","article-title":"225Ac-PSMA-617\/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience","volume":"47","author":"Khreish","year":"2019","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2026.119190_bib91","doi-asserted-by":"crossref","first-page":"739","DOI":"10.2967\/jnumed.124.268959","article-title":"Dansylated amino acid-modified long-acting PSMA derivatives (68)Ga\/(177)Lu-LNC1011 as prostate cancer theranostics","volume":"66","author":"Yang","year":"2025","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2026.119190_bib92","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1021\/acsmedchemlett.4c00324","article-title":"Synthesis and preclinical evaluation of a bispecific PSMA-617\/RM2 heterodimer targeting prostate cancer","volume":"15","author":"Liolios","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119190_bib93","series-title":"StatPearls, StatPearls Publishing Copyright \u00a9 2025","article-title":"Physiology, somatostatin","author":"O'Toole","year":"2025"},{"key":"10.1016\/j.ejmech.2026.119190_bib94","series-title":"Biochemistry, G Protein Coupled Receptors","author":"Rehman","year":"2018"},{"key":"10.1016\/j.ejmech.2026.119190_bib95","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1091\/mbc.e03-02-0069","article-title":"Critical role of Src and SHP-2 in sst2 somatostatin receptor-mediated activation of SHP-1 and inhibition of cell proliferation","volume":"14","author":"Ferjoux","year":"2003","journal-title":"Mol. Biol. Cell"},{"key":"10.1016\/j.ejmech.2026.119190_bib96","first-page":"471","article-title":"Distribution of somatostatin receptors in normal and neoplastic human tissues: recent advances and potential relevance","volume":"70","author":"Reubi","year":"1997","journal-title":"Yale J. Biol. Med."},{"key":"10.1016\/j.ejmech.2026.119190_bib97","doi-asserted-by":"crossref","first-page":"R81","DOI":"10.1530\/ERC-20-0360","article-title":"Somatostatin receptor radionuclide therapy in neuroendocrine tumors","volume":"28","author":"Haider","year":"2021","journal-title":"Endocr. Relat. Cancer"},{"key":"10.1016\/j.ejmech.2026.119190_bib98","doi-asserted-by":"crossref","first-page":"167","DOI":"10.2967\/jnumed.118.213496","article-title":"New developments in peptide receptor radionuclide therapy","volume":"60","author":"Nicolas","year":"2019","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2026.119190_bib99","doi-asserted-by":"crossref","first-page":"940","DOI":"10.7150\/thno.91268","article-title":"Peptide receptor radionuclide therapy combinations for neuroendocrine tumours in ongoing clinical trials: status 2023","volume":"14","author":"di Santo","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2026.119190_bib100","doi-asserted-by":"crossref","DOI":"10.3390\/ph12030114","article-title":"Lutathera(\u00ae): the first FDA- and EMA-approved radiopharmaceutical for peptide receptor radionuclide therapy","volume":"12","author":"Hennrich","year":"2019","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.ejmech.2026.119190_bib101","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1021\/acs.bioconjchem.8b00341","article-title":"Novel structural modification based on Evans blue dye to improve pharmacokinetics of a Somastostatin-Receptor-Based Theranostic agent","volume":"29","author":"Bandara","year":"2018","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2026.119190_bib102","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/jlcr.3755","article-title":"Design and development of the theranostic pair (177) Lu-OPS201\/(68) Ga-OPS202 for targeting somatostatin receptor expressing tumors","volume":"62","author":"Mansi","year":"2019","journal-title":"J. Label. Compd. Radiopharm."},{"key":"10.1016\/j.ejmech.2026.119190_bib103","first-page":"1310","article-title":"Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC","volume":"46","author":"Forrer","year":"2005","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2026.119190_bib104","doi-asserted-by":"crossref","first-page":"1595","DOI":"10.1007\/s00259-021-05632-5","article-title":"Efficacy and safety of (225)Ac-DOTATATE targeted alpha therapy in metastatic paragangliomas: a pilot study","volume":"49","author":"Yadav","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2026.119190_bib105","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1002\/cncr.23469","article-title":"Functional imaging of neuroendocrine tumors with combined PET\/CT using 68Ga-DOTATATE (DOTA-DPhe1,Tyr3-octreotate) and 18F-FDG","volume":"112","author":"Kayani","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2026.119190_bib106","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15041110","article-title":"Lutathera(\u00ae) orphans: state of the art and future application of radioligand therapy with (177)Lu-DOTATATE","volume":"15","author":"Urso","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2026.119190_bib107","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1021\/acs.bioconjchem.8b00341","article-title":"Novel structural modification based on Evans blue dye to improve pharmacokinetics of a somastostatin-receptor-based theranostic agent","volume":"29","author":"Bandara","year":"2018","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2026.119190_bib108","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.3390\/ph14121265","article-title":"Distinct in vitro binding profile of the somatostatin receptor subtype 2 antagonist [177Lu] Lu-OPS201 compared to the agonist [177Lu] Lu-DOTA-TATE","volume":"14","author":"Mansi","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2026.119190_bib109","doi-asserted-by":"crossref","first-page":"47","DOI":"10.7150\/thno.7447","article-title":"Prospective of 68Ga-radiopharmaceutical development","volume":"4","author":"Velikyan","year":"2013","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2026.119190_bib110","doi-asserted-by":"crossref","first-page":"9215","DOI":"10.1038\/s41598-022-13142-z","article-title":"Discovery of the cyclotide caripe 11 as a ligand of the cholecystokinin-2 receptor","volume":"12","author":"Taghizadeh","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2026.119190_bib111","doi-asserted-by":"crossref","first-page":"10289","DOI":"10.1021\/acs.jmedchem.3c00377","article-title":"Development of highly potent clinical candidates for Theranostic applications against Cholecystokinin-2 receptor positive cancers","volume":"66","author":"Corlett","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119190_bib112","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.7522","article-title":"Assessment of cholecystokinin 2 receptor (CCK2R) in neoplastic tissue","volume":"7","author":"Roy","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2026.119190_bib113","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2967\/jnumed.114.144998","article-title":"Evaluation of a nonpeptidic ligand for imaging of cholecystokinin 2 receptor\u2013expressing cancers","volume":"56","author":"Wayua","year":"2015","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2026.119190_bib114","doi-asserted-by":"crossref","first-page":"5776","DOI":"10.3390\/cancers13225776","article-title":"Update on preclinical development and clinical translation of Cholecystokinin-2 receptor targeting radiopharmaceuticals","volume":"13","author":"von Guggenberg","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2026.119190_bib115","doi-asserted-by":"crossref","first-page":"7112","DOI":"10.2174\/0929867327666200625143035","article-title":"Cholecystokinin-2 receptor targeting with radiolabeled peptides: current status and future directions","volume":"27","author":"Klingler","year":"2020","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119190_bib116","doi-asserted-by":"crossref","first-page":"666","DOI":"10.3390\/pharmaceutics14030666","article-title":"Nonpeptidic Z360-Analogs tagged with trivalent radiometals as Anti-CCK2R cancer Theranostic agents: a preclinical Study","volume":"14","author":"Nock","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2026.119190_bib117","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.2967\/jnumed.118.221283","article-title":"DOTA-MGS5, a new Cholecystokinin-2 receptor-targeting peptide analog with an optimized targeting profile for theranostic use","volume":"60","author":"Klingler","year":"2018","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2026.119190_bib118","doi-asserted-by":"crossref","DOI":"10.3390\/ph16020278","article-title":"Effects of side chain and peptide bond modifications on the targeting properties of stabilized minigastrin analogs","volume":"16","author":"Zavvar","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.ejmech.2026.119190_bib119","doi-asserted-by":"crossref","first-page":"3045","DOI":"10.1021\/acs.molpharmaceut.7b00241","article-title":"177)Lu labeled cyclic minigastrin analogues with therapeutic activity in CCK2R expressing tumors: preclinical evaluation of a kit formulation","volume":"14","author":"Rangger","year":"2017","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2026.119190_bib120","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.7150\/thno.89701","article-title":"Precision peptide theranostics: developing N- to C-terminus optimized theranostics targeting cholecystokinin-2 receptor","volume":"14","author":"Rahimi","year":"2024","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2026.119190_bib121","doi-asserted-by":"crossref","DOI":"10.3390\/ph12010013","article-title":"Cholecystokinin-2 receptor targeting with novel C-terminally stabilized HYNIC-minigastrin analogs radiolabeled with Technetium-99m","volume":"12","author":"Klingler","year":"2019","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.ejmech.2026.119190_bib122","doi-asserted-by":"crossref","first-page":"393","DOI":"10.2967\/jnumed.118.207845","article-title":"Targeting of the Cholecystokinin-2 receptor with the minigastrin analog (177)Lu-DOTA-PP-F11N: does the use of protease inhibitors further improve in vivo distribution?","volume":"60","author":"Sauter","year":"2019","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2026.119190_bib123","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27062034","article-title":"Automated synthesis of (68)Ga-Labeled DOTA-MGS8 and preclinical characterization of Cholecystokinin-2 receptor targeting","volume":"27","author":"H\u00f6rmann","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119190_bib124","doi-asserted-by":"crossref","first-page":"5400","DOI":"10.1016\/j.bmc.2010.05.031","article-title":"Development of a new radioligand for cholecystokinin receptor subtype 2 scintigraphy: from molecular modeling to in vivo evaluation","volume":"18","author":"Brillouet","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119190_bib125","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.7150\/thno.24378","article-title":"Site-specific stabilization of minigastrin analogs against enzymatic degradation for enhanced cholecystokinin-2 receptor targeting","volume":"8","author":"Klingler","year":"2018","journal-title":"Theranostics"},{"key":"10.1016\/j.ejmech.2026.119190_bib126","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2967\/jnumed.106.037085","article-title":"Selection of radiolabeled gastrin analogs for peptide receptor-targeted radionuclide therapy","volume":"48","author":"Mather","year":"2007","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2026.119190_bib127","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s00259-024-06979-1","article-title":"Radiopharmaceutical formulation and preliminary clinical dosimetry of [177Lu]Lu-DOTA-MGS5 for application in peptide receptor radionuclide therapy","volume":"52","author":"Zavvar","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2026.119190_bib128","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00259-011-1816-y","article-title":"Comparison of the binding and internalization properties of 12 DOTA-coupled and 111In-labelled CCK2\/gastrin receptor binding peptides: a collaborative project under COST Action BM0607","volume":"38","author":"Aloj","year":"2011","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2026.119190_bib129","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1007\/s11307-011-0506-2","article-title":"Preclinical evaluation of radiolabeled DOTA-derivatized cyclic minigastrin analogs for targeting cholecystokinin receptor expressing malignancies","volume":"14","author":"von Guggenberg","year":"2011","journal-title":"Mol. Imag. Biol."},{"key":"10.1016\/j.ejmech.2026.119190_bib130","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1021\/acs.molpharmaceut.0c00605","article-title":"[(99m)Tc]Tc-DGA1, a promising CCK(2)R-Antagonist-Based tracer for tumor diagnosis with single-photon emission computed tomography","volume":"17","author":"Kaloudi","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2026.119190_bib131","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.3390\/ph15121467","article-title":"Introduction of a SiFA moiety into the D-Glutamate chain of DOTA-PP-F11N results in radiohybrid-based CCK-2R-Targeted compounds with improved pharmacokinetics in vivo","volume":"15","author":"Holzleitner","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2026.119190_bib132","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40644-024-00658-y","article-title":"Advances of radiolabeled GRPR ligands for PET\/CT imaging of cancers","volume":"24","author":"Ma","year":"2024","journal-title":"Cancer Imaging"},{"key":"10.1016\/j.ejmech.2026.119190_bib133","series-title":"Molecular Imaging and Contrast Agent Database (MICAD)","article-title":"[(18)F]Fluorobenzyl-bombesin[7-14]-c(RGDyK)","author":"Leung","year":"2004"},{"key":"10.1016\/j.ejmech.2026.119190_bib134","doi-asserted-by":"crossref","first-page":"4199","DOI":"10.1021\/acs.molpharmaceut.4c00066","article-title":"Radiopharmaceuticals targeting gastrin-releasing peptide receptor for diagnosis and therapy of prostate cancer","volume":"21","author":"Zou","year":"2024","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2026.119190_bib135","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.cpet.2017.02.007","article-title":"Theranostic prospects of gastrin-releasing peptide receptor\u2013radioantagonists in oncology","volume":"12","author":"Maina","year":"2017","journal-title":"Pet. Clin."},{"key":"10.1016\/j.ejmech.2026.119190_bib136","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.nucmedbio.2022.02.004","article-title":"Know thy tumour: biomarkers to improve treatment of molecular radionuclide therapy","author":"O'Neill","year":"2022","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.ejmech.2026.119190_bib137","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2174\/09298673113209990219","article-title":"Peptide-based radiopharmaceuticals for targeted tumor therapy","volume":"21","author":"Dong","year":"2013","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejmech.2026.119190_bib138","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.2967\/jnumed.111.094375","article-title":"Bombesin antagonist\u2013based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor\u2013positive tumors","volume":"52","author":"Abiraj","year":"2011","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2026.119190_bib139","doi-asserted-by":"crossref","DOI":"10.1186\/s41181-024-00241-7","article-title":"Unnatural amino acid substitutions to improve in vivo stability and tumor uptake of 68Ga-labeled GRPR-targeted TacBOMB2 derivatives for cancer imaging with positron emission tomography","volume":"9","author":"Wang","year":"2024","journal-title":"EJNMMI Radiopharmacy and Chemistry"},{"key":"10.1016\/j.ejmech.2026.119190_bib140","doi-asserted-by":"crossref","first-page":"5093","DOI":"10.3390\/cancers13205093","article-title":"[99mTc]Tc-DB15 in GRPR-targeted tumor imaging with SPECT: from preclinical evaluation to the first clinical outcomes","volume":"13","author":"Nock","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2026.119190_bib141","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1007\/s10967-018-6396-x","article-title":"Comparative cell uptake study of FITC-\/177Lu-labeled RM26 monomer, dimer and trimer on PC-3: improving binding affinity of gastrin releasing peptide receptor (GRPR) antagonist via bivalency\/trivalency","volume":"319","author":"Zhuo","year":"2019","journal-title":"J. Radioanal. Nucl. Chem."},{"key":"10.1016\/j.ejmech.2026.119190_bib142","doi-asserted-by":"crossref","first-page":"6385","DOI":"10.1021\/acs.molpharmaceut.4c00952","article-title":"Synthesis and evaluation of (68)Ga- and (177)Lu-Labeled [Pro(14)]bombesin(8-14) derivatives for detection and radioligand therapy of gastrin-releasing peptide receptor-expressing cancer","volume":"21","author":"Wang","year":"2024","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2026.119190_bib143","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1007\/s00330-022-08982-2","article-title":"Value of (68)Ga-labeled bombesin antagonist (RM2) in the detection of primary prostate cancer comparing with [(18)F]fluoromethylcholine PET-CT and multiparametric MRI-a phase I\/II study","volume":"33","author":"Beheshti","year":"2023","journal-title":"Eur. Radiol."},{"key":"10.1016\/j.ejmech.2026.119190_bib144","article-title":"Design and synthesis of GRPR-targeted PET probes based on Dar derivatives for imaging of prostate cancer","volume":"67","author":"Luo","year":"2025","journal-title":"Nanomedicine"},{"key":"10.1016\/j.ejmech.2026.119190_bib145","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/jlcr.3795","article-title":"Synthesis, radiolabeling, and evaluation of gastrin releasing peptide receptor antagonist (68) Ga-HBED-CC-RM26","volume":"62","author":"Satpati","year":"2019","journal-title":"J. Label. Compd. Radiopharm."},{"key":"10.1016\/j.ejmech.2026.119190_bib146","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s41181-024-00242-6","article-title":"Preclinical evaluation of new GRPR-antagonists with improved metabolic stability for radiotheranostic use in oncology","volume":"9","author":"Kanellopoulos","year":"2024","journal-title":"EJNMMI Radiopharm Chem"},{"key":"10.1016\/j.ejmech.2026.119190_bib147","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2967\/jnumed.116.178889","article-title":"Theranostic perspectives in prostate cancer with the gastrin-releasing peptide receptor antagonist NeoBOMB1: preclinical and first clinical results","volume":"58","author":"Nock","year":"2017","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2026.119190_bib148","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.2967\/jnumed.124.268101","article-title":"Preclinical investigation of [(212)Pb]Pb-DOTAM-GRPR1 for peptide receptor radionuclide therapy in a prostate tumor model","volume":"65","author":"Saidi","year":"2024","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2026.119190_bib149","article-title":"Synthesis and evaluation of the first (68)Ga-Labeled C-Terminal hydroxamate-derived gastrin-releasing peptide receptor-targeted tracers for cancer imaging with positron emission tomography","volume":"29","author":"Wang","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119190_bib150","doi-asserted-by":"crossref","first-page":"3851","DOI":"10.1007\/s00259-023-06364-4","article-title":"Side-by-side comparison of the two widely studied GRPR radiotracers, radiolabeled NeoB and RM2, in a preclinical setting","volume":"50","author":"Damiana","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2026.119190_bib151","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2024-CT290","article-title":"Abstract CT290: trial in progress: evaluation of the safety, tolerability, whole-body distribution, radiation dosimetry and antitumor activity of 177Lu-NeoB in patients with advanced solid tumors expressing gastrin-releasing peptide receptor (GRPR)","volume":"84","author":"Mittra","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119190_bib152","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1007\/s11307-023-01851-4","article-title":"The balance between the therapeutic efficacy and safety of [177Lu]Lu-NeoB in a preclinical prostate cancer model","volume":"26","author":"Verhoeven","year":"2023","journal-title":"Mol. Imag. Biol."},{"key":"10.1016\/j.ejmech.2026.119190_bib153","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2967\/jnumed.116.176636","article-title":"68Ga\/177Lu-NeoBOMB1, a novel radiolabeled GRPR antagonist for Theranostic use in oncology","volume":"58","author":"Dalm","year":"2017","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2026.119190_bib154","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.nucmedbio.2014.10.008","article-title":"Preclinical pharmacokinetic, biodistribution, imaging and therapeutic efficacy of 177Lu-Labeled glycated bombesin analogue for gastrin-releasing peptide receptor-positive prostate tumor targeting","volume":"42","author":"Lim","year":"2015","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.ejmech.2026.119190_bib155","article-title":"Theranostic targeting of GRPR and PSMA in prostate cancer","volume":"2023","author":"Abouzayed","year":"2023","journal-title":"Acta Univ. Upsal."},{"key":"10.1016\/j.ejmech.2026.119190_bib156","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1021\/acs.bioconjchem.5b00687","article-title":"Novel bispecific PSMA\/GRPr targeting radioligands with optimized pharmacokinetics for improved PET imaging of prostate cancer","volume":"27","author":"Liolios","year":"2016","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.ejmech.2026.119190_bib157","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3390\/pharmaceutics11070358","article-title":"Synthesis and preclinical evaluation of radio-iodinated GRPR\/PSMA bispecific heterodimers for the theranostics application in prostate cancer","volume":"11","author":"Abouzayed","year":"2019","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2026.119190_bib158","first-page":"21","article-title":"Diagnostic role of gastrin-releasing peptide receptors in oncology, radiation diagnostics","volume":"12","author":"Korol","year":"2021","journal-title":"Radiat. Ther."},{"key":"10.1016\/j.ejmech.2026.119190_bib159","doi-asserted-by":"crossref","first-page":"3033","DOI":"10.2174\/138161208786404335","article-title":"Nuclear imaging of prostate cancer with Gastrin-Releasing-Peptide- receptor targeted radiopharmaceuticals","volume":"14","author":"Ananias","year":"2008","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ejmech.2026.119190_bib160","doi-asserted-by":"crossref","DOI":"10.1016\/j.nucmedbio.2024.108961","article-title":"Gastrin-releasing peptide receptor as theranostic target in estrogen-receptor positive breast cancer: a preclinical study of the theranostic pair [55Co]Co- and [177Lu]Lu-DOTA-RM26","author":"Baun","year":"2024","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.ejmech.2026.119190_bib161","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0170536","article-title":"Prospects of targeting the Gastrin releasing peptide receptor and somatostatin receptor 2 for nuclear imaging and therapy in metastatic breast cancer","volume":"12","author":"Dalm","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2026.119190_bib162","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.2967\/jnumed.115.160739","article-title":"Clinical relevance of targeting the gastrin-releasing peptide receptor, somatostatin receptor 2, or chemokine C-X-C motif receptor 4 in breast cancer for imaging and therapy","volume":"56","author":"Dalm","year":"2015","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2026.119190_bib163","article-title":"Dual 68Ga-labeled peptide-based radiopharmaceuticals to address tumor heterogeneity","author":"Previti","year":"2024"},{"key":"10.1016\/j.ejmech.2026.119190_bib164","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1021\/acsmedchemlett.5c00032","article-title":"Development of novel gastrin-releasing peptide receptor-targeted radioligand with albumin binder to improve accumulation in tumor","volume":"16","author":"Tsuchihashi","year":"2025","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2026.119190_bib165","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1007\/s00259-023-06169-5","article-title":"A radiohybrid theranostics ligand labeled with fluorine-18 and lutetium-177 for fibroblast activation protein-targeted imaging and radionuclide therapy","volume":"50","author":"Yang","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2026.119190_bib166","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1007\/s00259-023-06144-0","article-title":"Fibroblast activation protein-targeted radionuclide therapy: background, opportunities, and challenges of first (pre)clinical studies","volume":"50","author":"Priv\u00e9","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2026.119190_bib167","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1186\/s13046-022-02519-7","article-title":"Patient-specific modeling of stroma-mediated chemoresistance of pancreatic cancer using a three-dimensional organoid-fibroblast co-culture system","volume":"41","author":"Schuth","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119190_bib168","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1007\/s12149-023-01873-6","article-title":"Recent topics in fibroblast activation protein inhibitor-PET\/CT: clinical and pharmacological aspects","volume":"38","author":"Nakamoto","year":"2024","journal-title":"Ann. Nucl. Med."},{"key":"10.1016\/j.ejmech.2026.119190_bib169","doi-asserted-by":"crossref","first-page":"2935","DOI":"10.1007\/s00259-023-06338-6","article-title":"Fibroblast activation protein (FAP)-targeted radionuclide therapy: which ligand is the best?","volume":"50","author":"Chakravarty","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2026.119190_bib170","doi-asserted-by":"crossref","first-page":"3461","DOI":"10.1007\/s00259-024-06763-1","article-title":"[68Ga]Ga-FAPI-46 PET\/CT for penile cancer \u2013 a feasibility study","volume":"51","author":"Eismann","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2026.119190_bib171","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s11307-024-01935-9","article-title":"[68Ga]Ga-labeled FAPI conjugated with gly-pro sequence for PET imaging of malignant tumors","volume":"26","author":"Shang","year":"2024","journal-title":"Mol. Imag. Biol."},{"key":"10.1016\/j.ejmech.2026.119190_bib172","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2967\/jnumed.120.259192","article-title":"Feasibility, biodistribution, and preliminary dosimetry in peptide-targeted radionuclide therapy of diverse adenocarcinomas using (177)Lu-FAP-2286: first-in-humans results","volume":"63","author":"Baum","year":"2022","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2026.119190_bib173","article-title":"FAP-targeted radioligand therapy with (68)Ga\/(177)Lu-DOTA-2P(FAPI)(2) enhance immunogenicity and synergize with PD-L1 inhibitors for improved antitumor efficacy","volume":"13","author":"Chen","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ejmech.2026.119190_bib174","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1158\/1078-0432.CCR-23-1983","article-title":"Fibroblast activation protein-targeted radioligand therapy with 177Lu-EB-FAPI for metastatic radioiodine-refractory thyroid cancer: first-in-human, dose-escalation study","volume":"29","author":"Fu","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119190_bib175","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1007\/s00259-024-06914-4","article-title":"Efficient \u03b1 and \u03b2(-) radionuclide therapy targeting fibroblast activation protein-\u03b1 in an aggressive preclinical mouse tumour model","volume":"52","author":"Ceuppens","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2026.119190_bib176","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1007\/s00259-024-06623-y","article-title":"Peptidic heterodimer-based radiotracer targeting fibroblast activation protein and integrin \u03b1(v)\u03b2(3)","volume":"51","author":"Liu","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2026.119190_bib177","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.cpet.2023.02.007","article-title":"Fibroblast activation protein inhibitor theranostics","volume":"18","author":"Mori","year":"2023","journal-title":"Pet. Clin."},{"key":"10.1016\/j.ejmech.2026.119190_bib178","article-title":"Based on small molecules: development and application of fibroblast activation protein inhibitors radiopharmaceutical in tumor precision therapy","volume":"16","author":"Luo","year":"2025","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2026.119190_bib179","doi-asserted-by":"crossref","DOI":"10.1186\/s41181-024-00283-x","article-title":"In vitro and in vivo analyses of eFAP: a novel FAP-targeting small molecule for radionuclide theranostics and other oncological interventions","volume":"9","author":"van der Heide","year":"2024","journal-title":"EJNMMI Radiopharmacy and Chemistry"},{"key":"10.1016\/j.ejmech.2026.119190_bib180","doi-asserted-by":"crossref","first-page":"5744","DOI":"10.3390\/cancers13225744","article-title":"Radioligands targeting fibroblast activation protein (FAP)","volume":"13","author":"Lindner","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2026.119190_bib181","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/s00259-024-06891-8","article-title":"Detection of tumour heterogeneity in patients with advanced, metastatic castration-resistant prostate cancer on [68Ga]Ga-\/[18F]F-PSMA-11\/-1007, [68Ga]Ga-FAPI-46 and 2-[18F]FDG PET\/CT: a pilot study","volume":"52","author":"Pabst","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2026.119190_bib182","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1007\/s00259-022-05842-5","article-title":"Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy","volume":"49","author":"Zboralski","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2026.119190_bib183","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1007\/s00259-024-06703-z","article-title":"Clinical translation of a novel FAPI dimer [68Ga]Ga-LNC1013","volume":"51","author":"Tan","year":"2024","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2026.119190_bib184","doi-asserted-by":"crossref","first-page":"3640","DOI":"10.1021\/acs.molpharmaceut.2c00424","article-title":"Development of fibroblast activation protein inhibitor-based dimeric radiotracers with improved tumor retention and antitumor efficacy","volume":"19","author":"Zhao","year":"2022","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ejmech.2026.119190_bib185","article-title":"Antitumor efficacy and potential mechanism of FAP-targeted radioligand therapy combined with immune checkpoint blockade","volume":"9","author":"Zhao","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.119190_bib186","doi-asserted-by":"crossref","first-page":"4740","DOI":"10.1158\/1078-0432.CCR-23-1983","article-title":"Fibroblast activation protein-targeted radioligand therapy with 177Lu-EB-FAPI for metastatic radioiodine-refractory thyroid cancer: first-in-human, dose-escalation study","volume":"29","author":"Fu","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119190_bib187","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/s41586-024-07461-6","article-title":"Covalent targeted radioligands potentiate radionuclide therapy","volume":"630","author":"Cui","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2026.119190_bib188","doi-asserted-by":"crossref","first-page":"345","DOI":"10.3390\/pharmaceutics16030345","article-title":"Beyond small molecules: antibodies and peptides for fibroblast activation protein targeting radiopharmaceuticals","volume":"16","author":"Sun","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2026.119190_bib189","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1007\/s00259-023-06300-6","article-title":"An antibody-radionuclide conjugate targets fibroblast activation protein for cancer therapy","volume":"50","author":"Xu","year":"2023","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2026.119190_bib190","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1007\/s00259-024-06979-1","article-title":"Radiopharmaceutical formulation and preliminary clinical dosimetry of [177Lu]Lu-DOTA-MGS5 for application in peptide receptor radionuclide therapy","volume":"52","author":"Zavvar","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2026.119190_bib191","article-title":"Gastrin-releasing peptide receptor as theranostic target in estrogen-receptor positive breast cancer: a preclinical study of the theranostic pair [(55)Co]Co- and [(177)Lu]Lu-DOTA-RM26","volume":"138\u2013139","author":"Baun","year":"2024","journal-title":"Nucl. Med. Biol."},{"key":"10.1016\/j.ejmech.2026.119190_bib192","doi-asserted-by":"crossref","first-page":"277","DOI":"10.2214\/AJR.17.18264","article-title":"Targeted radionuclide therapy: an evolution toward precision cancer treatment","volume":"209","author":"Jadvar","year":"2017","journal-title":"Am. J. Roentgenol."},{"key":"10.1016\/j.ejmech.2026.119190_bib193","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.3390\/pharmaceutics15051378","article-title":"Optimizing the safety and efficacy of bio-radiopharmaceuticals for cancer therapy","volume":"15","author":"Funeh","year":"2023","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2026.119190_bib194","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.3390\/pharmaceutics16111458","article-title":"Optimization processes of clinical chelation-based radiopharmaceuticals for pathway-directed targeted radionuclide therapy in oncology","volume":"16","author":"Tomiyoshi","year":"2024","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ejmech.2026.119190_bib195","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2022.114538","article-title":"Imaging-guided targeted radionuclide tumor therapy: from concept to clinical translation","volume":"190","author":"Sun","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ejmech.2026.119190_bib196","article-title":"Prospects of nano-theranostic approaches against breast and cervical cancer","volume":"1879","author":"Ria","year":"2024","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.ejmech.2026.119190_bib197","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.2967\/jnumed.120.248062","article-title":"Combination strategies to improve targeted radionuclide therapy","volume":"61","author":"Chan","year":"2020","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.ejmech.2026.119190_bib198","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3390\/ph18020257","article-title":"Nano-radiopharmaceuticals in Colon cancer: current applications, challenges, and future directions","volume":"18","author":"Alkatheeri","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2026.119190_bib199","article-title":"Targeted drug conjugates in cancer therapy: challenges and opportunities, pharmaceutical","volume":"2","author":"Jia","year":"2024","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2026.119190_bib200","doi-asserted-by":"crossref","first-page":"125","DOI":"10.22270\/jddt.v15i3.7011","article-title":"Comprehensive overview on antibody drug Conjugates- A promising approach in cancer therapy","volume":"15","author":"Muppa","year":"2025","journal-title":"J. Drug Deliv. Therapeut."},{"key":"10.1016\/j.ejmech.2026.119190_bib201","doi-asserted-by":"crossref","first-page":"6968","DOI":"10.3390\/ijms26146968","article-title":"Effects of targeted radionuclide therapy on cancer cells beyond the ablative radiation dose","volume":"26","author":"Ferro-Flores","year":"2025","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2026.119190_bib202","doi-asserted-by":"crossref","first-page":"5231","DOI":"10.3390\/molecules27165231","article-title":"Radiopharmaceutical treatments for cancer therapy, radionuclides characteristics, applications, and challenges","volume":"27","author":"Salih","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2026.119190_bib203","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2022.1020188","article-title":"Development of radiopharmaceuticals for targeted alpha therapy: where do we stand?","volume":"9","author":"Pallares","year":"2022","journal-title":"Front. Med."},{"key":"10.1016\/j.ejmech.2026.119190_bib204","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1002\/med.22093","article-title":"Comparison of radionuclide drug conjugates with boron neutron capture therapy: an overview of targeted charged particle radiation therapy","volume":"45","author":"Zhang","year":"2024","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2026.119190_bib205","doi-asserted-by":"crossref","DOI":"10.1515\/ejnm-2013-0025","article-title":"Novel radioisotope-based nanomedical approaches","volume":"5","author":"Olsen","year":"2013","journal-title":"Eur. J. Nanomed."},{"key":"10.1016\/j.ejmech.2026.119190_bib206","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccr.2025.217448","article-title":"Recent advances in coordination chemistry on the application and development of radiopharmaceuticals and boron neutron capture therapy","volume":"551","author":"Cai","year":"2026","journal-title":"Coord. Chem. Rev."},{"issue":"Suppl 2","key":"10.1016\/j.ejmech.2026.119190_bib207","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.rxeng.2024.03.010","article-title":"Introduction to iodinated contrasts: properties, intravenous administration and distribution throughout the body","volume":"66","author":"Cobos Alonso","year":"2024","journal-title":"Radiologia (Engl Ed)"},{"key":"10.1016\/j.ejmech.2026.119190_bib208","doi-asserted-by":"crossref","DOI":"10.2214\/AJR.23.30036","article-title":"Update on gadolinium-based contrast agent safety, from the AJR special series on contrast media","volume":"223","author":"Starekova","year":"2024","journal-title":"AJR Am. J. Roentgenol."},{"key":"10.1016\/j.ejmech.2026.119190_bib209","doi-asserted-by":"crossref","DOI":"10.1016\/j.currproblcancer.2021.100799","article-title":"Optimizing anti\u2013body drug conjugates and radiopharmaceuticals for precision therapy: the next frontier in precision oncology","volume":"45","author":"Subbiah","year":"2021","journal-title":"Curr. Probl. Cancer"},{"key":"10.1016\/j.ejmech.2026.119190_bib210","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1097\/PPO.0b013e318172d704","article-title":"Antibody-drug conjugates for cancer therapy","volume":"14","author":"Carter","year":"2008","journal-title":"Cancer J."},{"key":"10.1016\/j.ejmech.2026.119190_bib211","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s40164-024-00493-8","article-title":"Drug conjugates for the treatment of lung cancer: from drug discovery to clinical practice","volume":"13","author":"Zhou","year":"2024","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.ejmech.2026.119190_bib212","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2021.108106","article-title":"Antibody-drug conjugates: resurgent anticancer agents with multi-targeted therapeutic potential","volume":"236","author":"Ceci","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2026.119190_bib213","doi-asserted-by":"crossref","DOI":"10.1002\/cmdc.202300720","article-title":"Small molecule\u2010drug conjugates: opportunities for the development of targeted anticancer drugs","volume":"19","author":"Zhang","year":"2024","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ejmech.2026.119190_bib214","doi-asserted-by":"crossref","first-page":"394","DOI":"10.3390\/biomimetics10060394","article-title":"Radionuclide-labeled biomaterials: a novel strategy for tumor-targeted therapy","volume":"10","author":"Zhang","year":"2025","journal-title":"Biomimetics"},{"key":"10.1016\/j.ejmech.2026.119190_bib215","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1007\/s00259-021-05591-x","article-title":"Fatty acid-conjugated radiopharmaceuticals for fibroblast activation protein-targeted radiotherapy","volume":"49","author":"Zhang","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imag."},{"key":"10.1016\/j.ejmech.2026.119190_bib216","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1021\/cbmi.4c00030","article-title":"Peptide PET imaging: a review of recent developments and a look at the future of radiometal-labeled peptides in medicine","volume":"2","author":"Shabsigh","year":"2024","journal-title":"Chem Biomed Imaging"},{"key":"10.1016\/j.ejmech.2026.119190_bib217","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41392-024-02107-5","article-title":"Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines","volume":"10","author":"Xiao","year":"2025","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2026.119190_bib218","doi-asserted-by":"crossref","first-page":"5242","DOI":"10.1158\/1538-7445.AM2022-5242","article-title":"Abstract 5242: rationally designing a radionuclide drug conjugate for heterogeneous genomically stable gastric cancer","volume":"82","author":"Yang","year":"2022","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2026.119190_bib219","doi-asserted-by":"crossref","first-page":"6447","DOI":"10.3390\/curroncol30070474","article-title":"Antibody\u2013drug conjugates in breast cancer: ascent to destiny and beyond\u2014A 2023 review","volume":"30","author":"Xiao","year":"2023","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ejmech.2026.119190_bib220","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jconrel.2023.08.038","article-title":"Nitric oxide-driven nanotherapeutics for cancer treatment","volume":"362","author":"Zhao","year":"2023","journal-title":"J. Contr. Release"},{"key":"10.1016\/j.ejmech.2026.119190_bib221","first-page":"429","article-title":"The next frontier in antibody-drug conjugates: challenges and opportunities in cancer and autoimmune therapy","volume":"8","author":"Zhou","year":"2025","journal-title":"Cancer Drug Resistance"},{"key":"10.1016\/j.ejmech.2026.119190_bib222","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/s41568-024-00679-6","article-title":"Combinatorial strategies to target RAS-driven cancers","volume":"24","author":"Perurena","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2026.119190_bib223","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.3390\/ph17101314","article-title":"Radiopharmaceuticals for pancreatic cancer: a review of current approaches and future directions","volume":"17","author":"Calistri","year":"2024","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2026.119190_bib224","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2019.00560","article-title":"Radiopharmaceuticals for persistent or recurrent uterine cervix cancer","volume":"9","author":"Kunos","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2026.119190_bib225","first-page":"35","article-title":"Targeted radionuclide therapy: practical applications and future prospects","volume":"8","author":"Zukotynski","year":"2016","journal-title":"Biomarkers Cancer"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426006355?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523426006355?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:16:56Z","timestamp":1788049016000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523426006355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":225,"alternative-id":["S0223523426006355"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119190","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeted radionuclide-drug conjugates: Current status and perspectives","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2026.119190","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"119190"}}